ALONG: An Open-Label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding in Previously Treated Subjects With Severe Hemophilia A

Trial Profile

ALONG: An Open-Label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding in Previously Treated Subjects With Severe Hemophilia A

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Efmoroctocog alfa (Primary) ; Rurioctocog alfa
  • Indications Haemophilia A
  • Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
  • Acronyms A-LONG; ALONG
  • Sponsors Biogen Idec
  • Most Recent Events

    • 12 Dec 2017 Results of a subgroup analysis assessing clinical outcomes in patients from A-LONG and the ASPIRE studies who were exposed to a weekly dosing interval (n=43), presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 10 Dec 2017 Results of post hoc analysis from A-LONG and ASPIRE studies published in a Bioverativ media release.
    • 01 Nov 2017 According to a Bioverativ media release, longitudinal analysis from the study will be presented at the 59th Annual Meeting of the American Society of Hematology (ASH) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top